| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_777a7d4b6d214f486f77cccc5afc193d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d6559372bde7c7c71d22286457328c86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7bce595c861dba361078ba893e4713be |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-351
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-341
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4525
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-341
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-351
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4525
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 |
| filingDate |
2021-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_639a71ec957efed0d48ff328e704c86a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f3a9c065c8e9537f5af0d06218b15b55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96e06cb6e0b761c4637a53e6fa1ff04f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_036f28eb1f34f7ed7a35b3ac79c14744 |
| publicationDate |
2022-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-11458144-B1 |
| titleOfInvention |
Methods for using 5-HMF analogs with increased solubility to inhibit or reverse RBC sickling |
| abstract |
Methods for administering compounds provide a rapid treatment for sickle cell disease (SCD) to inhibit or reverse red blood cell sickling. The compounds are a group of 5-hydroxymethylfurfural (5-HMF) analogs modified to increase water-solubility. The compounds can be formulated in an aqueous carrier and administered intravenously for immediate uptake into red blood cells (RBCs) within hours, rather than days or weeks. In vitro experiments demonstrated rapid uptake into RBCs and increased O2 affinity of HbS to an equilibrium point within 30 to 90 minutes. The compounds have a desired level of safety as well as a short half-life, both of which are compatible with acute usage. Thus, the methods of treatment rapidly achieve therapeutic steady-state drug levels, making it possible to deliver a treatment in critical emergency care situations to prevent, reverse and otherwise treat acute sickling or anemia. |
| priorityDate |
2021-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |